Back to Search Start Over

Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.

Authors :
Ridolfi L
Fiorentini G
Guida M
Michiara M
Freschi A
Aitini E
Ballardini M
Bichisao E
Ridolfi R
Source :
Melanoma research [Melanoma Res] 2009 Apr; Vol. 19 (2), pp. 100-5.
Publication Year :
2009

Abstract

The efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 biochemotherapy were evaluated in advanced melanoma patients. The schedule consisted of fotemustine (100 mg/m) and cisplatin (75 mg/m) intravenous on day 1, followed by subcutaneous interleukin-2 at a dose of 4.5 MIU on days 3-5 and 8-12 and alpha-interferon at a dose of 3 MU three times/week, every 3 weeks for six cycles. Sixty patients were evaluated for tumour response, 12 of whom had brain metastases (BM). One patient (1.7%) with BM achieved a complete response and partial responses were observed in 10 patients (16.7%), including one BM patient. Overall response rate was 18.4 and 16.6% in BM patients (median response duration 8.2 months). Disease control, defined as overall response and stable disease, was 58.4% in all patients and 75% in patients with BM. Median time to progression was 3.2 months (4.2 months in BM patients). Median overall survival was 8.9 months (7.6 months in BM patients). Toxic events were mild to moderate. This combination was well tolerated and showed acceptable clinical activity, especially in BM patients.

Details

Language :
English
ISSN :
1473-5636
Volume :
19
Issue :
2
Database :
MEDLINE
Journal :
Melanoma research
Publication Type :
Academic Journal
Accession number :
19262411
Full Text :
https://doi.org/10.1097/CMR.0b013e328328f7ec